El análogo natural de almacenamiento y escape de CO2 de la cuenca de Gañuelas-Mazarrón: implicaciones para el comportamiento y la seguridad de un almacenamiento de CO2 en estado supercrítico

La cuenca terciaria de Gañuelas-Mazarrón se caracteriza por la existencia de un acuífero salino profundo (mayor que500m) sobresaturado en CO2 que puede considerarse como un análogo natural de un Almacenamiento Geológico Profundo (AGP) de CO2 de origen industrial. El CO2 de dicho acuífero ha permanecido oculto desde su almacenamiento hasta 1960-70, época en que comenzó la sobreexplotación de los acuíferos más someros de la cuenca con fines agrícolas . Actualmente este análogo natural está siendo objeto de estudio con el fin de determinar: i) las principales características de la citada cuenca y acuífero salino, incluyendo el origen del CO2; ii) los principales procesos de interacción agua/gas/roca que controlan la evolución de dicho sistema natural, y las principales analogías entre estos procesos naturales y los esperables en un AGP de CO2; iii) el comportamiento del sistema como almacenamiento natural de CO2; y iv) el comportamiento y la seguridad, a largo plazo, de un AGP artificial de CO2, aplicando los resultados del estudio del sistema natural citado

Identifying phenotypes involved in susceptibility to Schistosoma mansoni infection in F1B6CBA mice

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.Schistosomiasis is a disease with a strong genetic component influenced by socioeconomic and ecological factors. Epidemiological studies have identified several genetic regions involved in the schistosomiasis susceptibility. However, it is not well known what physiological traits are predisposing to the disease. The study of experimental infections in inbred mouse strains with variable genetic susceptibility to the disease offers a good opportunity to tackle this question. F1B6CBA hybrid between the most divergent strains was infected in order to characterize the immunophenotypes that correlate with the susceptibility of schistosomiasis disease in mice. Complete blood counts and immunophenotype were determined at 0, 3, 6, and 9 weeks post infection. Nine weeks after cercariae exposure, animals were perfused and worm recovery was assessed. A large number of hepatic lesions, a reduction in the eosinophil and basophil count in the acute phase of infection and the decreased number of monocytes, neutrophils and B-lymphocytes are phenotypes associated with increased susceptibility to S. mansoni infection.The present study was supported by a grant from the Areces Foundation (2010–13) and funding of the Junta de Castilla y Leon (Orden EDU/330/2008).Peer Reviewe

Combinatorial formulas for Kazhdan-Lusztig polynomials with respect to W-graph ideals

In \cite{y1} Yin generalized the definition of $W$-graph ideal $E_J$ in weighted Coxeter groups and introduced the weighted Kazhdan-Lusztig polynomials $\left \{ P_{x,y} \mid x,y\in E_J\right \}$, where $J$ is a subset of simple generators $S$. In this paper, we study the combinatorial formulas for those polynomials, which extend the results of Deodhar \cite{v3} and Tagawa \cite{h1}.Comment: 16 page

Unraveling heterogeneous susceptibility and the evolution of breast cancer using a systems biology approach

This is an Open Access article distributed under the terms of the Creative Commons Attribution License.-- et al.[Background]: An essential question in cancer is why individuals with the same disease have different clinical outcomes. Progress toward a more personalized medicine in cancer patients requires taking into account the underlying heterogeneity at different molecular levels. [Results]: Here, we present a model in which there are complex interactions at different cellular and systemic levels that account for the heterogeneity of susceptibility to and evolution of ERBB2-positive breast cancers. Our model is based on our analyses of a cohort of mice that are characterized by heterogeneous susceptibility to ERBB2-positive breast cancers. Our analysis reveals that there are similarities between ERBB2 tumors in humans and those of backcross mice at clinical, genomic, expression, and signaling levels. We also show that mice that have tumors with intrinsically high levels of active AKT and ERK are more resistant to tumor metastasis. Our findings suggest for the first time that a site-specific phosphorylation at the serine 473 residue of AKT1 modifies the capacity for tumors to disseminate. Finally, we present two predictive models that can explain the heterogeneous behavior of the disease in the mouse population when we consider simultaneously certain genetic markers, liver cell signaling and serum biomarkers that are identified before the onset of the disease. [Conclusions]: Considering simultaneously tumor pathophenotypes and several molecular levels, we show the heterogeneous behavior of ERBB2-positive breast cancer in terms of disease progression. This and similar studies should help to better understand disease variability in patient populations.JPL was partially supported by FEDER and MICINN (PLE2009-119), FIS (PI07/0057, PI10/00328, PIE14/00066), the Junta de Castilla y León (SAN673/SA26/08; SAN126/SA66/09, SA078A09, CSI034U13), the “Fundación Eugenio Rodríguez Pascual”, the Fundación Inbiomed (Instituto Oncológico Obra Social de la Caja Guipozcoa-San Sebastian, Kutxa), and the “Fundación Sandra Ibarra de Solidaridad frente al Cáncer”. AC was supported by MICINN (PLE2009-119). SCLL is funded by a JAEdoc Fellowship (CSIC)/FSE. MMSF and ABG are funded by fellowships from the Junta de Castilla y Leon. WR was supported by a Forschungsstipendium of the Deutsche Forschungsgemeinschaft (DFG) [RE 3108/1-1]. TN, BPB and DYL acknowledge support from the US Department of Energy Low-Dose SFA Program at Berkeley Lab [DE-AC02-05CH11231], the National Institutes of Health [RC1NS069177] and the California Breast Cancer Research Program [15IB-0063]. JHM was supported by the National Institutes of Health, a National Cancer Institute grant (R01 CA116481), and the Low-Dose Scientific Focus Area, Office of Biological and Environmental Research, US Department of Energy (DE-AC02-05CH11231).Peer Reviewe

Efficacy and safety of preoperative preparation with Lugol's iodine solution in euthyroid patients with Graves’ disease (LIGRADIS Trial): Study protocol for a multicenter randomized trial

Background: Currently, both the American Thyroid Association and the European Thyroid Association recom mend preoperative preparation with Lugol's Solution (LS) for patients undergoing thyroidectomy for Graves’ Disease (GD), but their recommendations are based on low-quality evidence. The LIGRADIS trial aims to pro vide evidence either to support or refute the systematic use of LS in euthyroid patients undergoing thyroidec tomy for GD. Methods: A multicenter randomized controlled trial will be performed. Patients ≥18 years of age, diagnosed with GD, treated with antithyroid drugs, euthyroid and proposed for total thyroidectomy will be eligible for inclusion. Exclusion criteria will be prior thyroid or parathyroid surgery, hyperparathyroidism that requires associated parathyroidectomy, thyroid cancer that requires adding a lymph node dissection, iodine allergy, consumption of lithium or amiodarone, medically unfit patients (ASA-IV), breastfeeding women, preoperative vocal cord palsy and planned endoscopic, video-assisted or remote access surgery. Between January 2020 and January 2022, 270 patients will be randomized for either receiving or not preoper ative preparation with LS. Researchers will be blinded to treatment assignment. The primary outcome will be the rate of postoperative complications: hypoparathyroidism, recurrent laryngeal nerve injury, hematoma, surgical site infection or death. Secondary outcomes will be intraoperative events (Thyroidectomy Difficulty Scale score, blood loss, recurrent laryngeal nerve neuromonitoring signal loss), operative time, postoperative length of stay, hospital readmissions, permanent complications and adverse events associated to LS. Conclusions: There is no conclusive evidence supporting the benefits of preoperative treatment with LS in this set ting. This trial aims to provide new insights into future Clinical Practice Guidelines recommendations. Trial registration: ClinicalTrials.gov identifier: NCT03980132

Eficacia de la dieta libre de gluten en el síndrome Gilles de la Tourette con enfermedad celíaca. Reporte de caso

Fundamentación: El síndrome Gilles de la Tourette es un proceso neuropsiquiátrico de causa desconocida caracterizado por múltiples tics. Los desórdenes relacionados al gluten cubren múltiples manifestaciones clínicas inmunológicas ante el consumo de gluten; incluyen la enfermedad celíaca y la sensibilidad al gluten no celíaca. Se han publicado casos de síndrome Gilles de la Tourette con sensibilidad al gluten no celíaca, pero ninguno relacionado con la enfermedad celíaca clásica. Reporte de caso: Paciente masculino de 20 años, con diagnóstico de EC desde la infancia y cuadro típico de Tourette diagnosticado recientemente. Mostró excelente respuesta y remisión clínica neurológica y conductual después de establecerse rigurosamente una dieta libre de gluten. Conclusiones: Es necesario incluir entre los grupos de riesgo de sensibilidad al gluten los niños con trastornos neuropsicológicos como los aquí referidos. La enfermedad celíaca clásica debe incluirse entre las posibles asociaciones con el síndrome Gilles de la Tourette. La dieta restrictiva también mejora en estos casos la evolución de ambas enfermedades

Hospital Epidemics Tracker (HEpiTracker): Description and pilot study of a mobile app to track COVID-19 in hospital workers

Background: Hospital workers have been the most frequently and severely affected professional group during the COVID-19 pandemic, and have a big impact on transmission. In this context, innovative tools are required to measure the symptoms compatible with COVID-19, the spread of infection, and testing capabilities within hospitals in real time. Objective: We aimed to develop and test an effective and user-friendly tool to identify and track symptoms compatible with COVID-19 in hospital workers. Methods: We developed and pilot tested Hospital Epidemics Tracker (HEpiTracker), a newly designed app to track the spread of COVID-19 among hospital workers. Hospital staff in 9 hospital centers across 5 Spanish regions (Andalusia, Balearics, Catalonia, Galicia, and Madrid) were invited to download the app on their phones and to register their daily body temperature, COVID-19-compatible symptoms, and general health score, as well as any polymerase chain reaction and serological test results. Results: A total of 477 hospital staff participated in the study between April 8 and June 2, 2020. Of note, both health-related (n=329) and non-health-related (n=148) professionals participated in the study; over two-thirds of participants (68.8%) were health workers (43.4% physicians and 25.4% nurses), while the proportion of non-health-related workers by center ranged from 40% to 85%. Most participants were female (n=323, 67.5%), with a mean age of 45.4 years (SD 10.6). Regarding smoking habits, 13.0% and 34.2% of participants were current or former smokers, respectively. The daily reporting of symptoms was highly variable across participating hospitals; although we observed a decline in adherence after an initial participation peak in some hospitals, other sites were characterized by low participation rates throughout the study period. Conclusions: HEpiTracker is an already available tool to monitor COVID-19 and other infectious diseases in hospital workers. This tool has already been tested in real conditions. HEpiTracker is available in Spanish, Portuguese, and English. It has the potential to become a customized asset to be used in future COVID-19 pandemic waves and other environments

Diagnostic Performance of the Fujifilm SILVAMP TB-LAM in Children with Presumptive Tuberculosis

Current diagnostics for tuberculosis (TB) only manage to confirm a small proportion of children with TB and require respiratory samples, which are difficult to obtain. There is a need for non-invasive biomarker-based tests as an alternative to sputum testing. Fujifilm SILVAMP TB lipoarabinomannan (FujiLAM), a lateral-flow test to detect lipoarabinomannan in urine, is a novel non-sputum-based point-of-care diagnostic reported to have increased sensitivity for the diagnosis of TB among human immunodeficiency virus (HIV)-infected adults. We evaluate the performance of FujiLAM in children with presumptive TB. Fifty-nine children attending a paediatric hospital in Haiti with compatible signs and symptoms of TB were examined using Xpert MTB/RIF, smear microscopy and X-rays, and classified according to the certainty of diagnosis into bacteriologically confirmed TB ( = 5), unconfirmed TB (bacteriologically negative, = 50) and unlikely TB ( = 4). Healthy children ( = 20) were enrolled as controls. FujiLAM sensitivity and specificity were 60% and 95% among children with confirmed TB. FujiLAM's high specificity and its characteristics as a point-of-care indicate the test has a good potential for the diagnosis of TB in children